Skip to main content

Neurological Disorder

Application of Anti-Motion Ultra-Fast Quantitative MRI in Neurological Disorder Imaging: Insights From Huntington's Disease


Background


Conventional quantitative MRI (qMRI) scan is time-consuming and highly sensitive to movements, posing great challenges for quantitative images of individuals with involuntary movements, such as Huntington's disease (HD).

Purpose


To evaluate the potential of our developed ultra-fast qMRI technique, multiple overlapping-echo detachment (MOLED), in overcoming involuntary head motion and its capacity to quantitatively assess tissue changes in HD.

Phantom/Subjects


A phantom comprising 13 tubes of MnCl2 at varying concentrations, 5 healthy volunteers (male/female: 1/4), 22 HD patients (male/female: 14/8) and 27 healthy controls (male/female: 15/12).

Field Strength/Sequence

3.0 T. MOLED-T2 sequence, MOLED-T2* sequence, T2-weighted spin-echo sequence, T1-weighted gradient echo sequence, and T2-dark-fluid sequence.

Assessment


T1-weighted images were reconstructed into high-resolution images, followed by segmentation to delineate regions of interest (ROIs). Subsequently, the MOLED T2 and T2* maps were aligned with the high-resolution images, and the ROIs were transformed into the MOLED image space using the transformation matrix and warp field. Finally, T2 and T2* values were extracted from the MOLED relaxation maps.

Statistical Tests


Bland–Altman analysis, independent t test, Mann–Whitney U test, Pearson correlation analysis, and Spearman correlation analysis, P < 0.05 was considered statistically significant.

Results


MOLED-T2 and MOLED-T2* sequences demonstrated good accuracy (Meandiff = − 0.20%, SDdiff = 1.05%, and Meandiff = −1.73%, SDdiff = 10.98%, respectively), and good repeatability (average intraclass correlation coefficient: 0.856 and 0.853, respectively). More important, MOLED T2 and T2* maps remained artifact-free across all HD patients, even in the presence of apparent head motions. Moreover, there were significant differences in T2 and T2* values across multiple ROIs between HD and controls.

Data Conclusion


The ultra-fast scanning capabilities of MOLED effectively mitigate the impact of head movements, offering a robust solution for quantitative imaging in HD. Moreover, T2 and T2* values derived from MOLED provide powerful capabilities for quantifying tissue changes.

Quantitative MRI scan is time-consuming and sensitive to movements. Consequently, obtaining quantitative images is challenging for patients with involuntary movements, such as those with Huntington's Disease (HD). In response, a newly developed MOLED technique has been introduced, promising to resist motion through ultra-fast scan. This technique has demonstrated excellent accuracy and reproducibility and importantly all HD patient's MOLED maps remained artifacts-free. Additionally, there were significant differences in T2 and T2∗ values across ROIs between HD and controls. The robust resistance of MOLED to motion makes it particularly suitable for quantitative assessments in patients prone to involuntary movements.

neurological disorder, brain disease, neurodegeneration, Parkinson’s disease, Alzheimer’s disease, epilepsy, multiple sclerosis, stroke, cognitive decline, dementia, neuroinflammation, traumatic brain injury, motor neuron disease, neurogenetics, neural pathways, CNS disorder, neuropathy, Huntington’s disease, brain tumors, neuroplasticity

#NeurologicalDisorder, #BrainHealth, #Neurodegeneration, #ParkinsonsDisease, #Alzheimers, #EpilepsyAwareness, #MultipleSclerosis, #StrokeRecovery, #CognitiveHealth, #DementiaAwareness, #Neuroinflammation, #BrainInjury, #MotorNeuronDisease, #Neurogenetics, #CNSDisorders, #Neuropathy, #HuntingtonsDisease, #BrainTumor, #Neuroplasticity, #NeuroResearch

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

Comments

Post a Comment

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Genetic Test

Genetic test eliminates progressive retinal atrophy in English shepherd dogs Researchers at the University of Cambridge recently published their findings in Genes after identifying the genetic mutation that is causing progressive retinal atrophy (PRA) in English shepherd dogs. PRA is a group of inherited diseases causing progressive degeneration of the light sensitive cells within the back of the eyes. When it comes to PRA in dogs, they are born with normal vision but by the age of 4-5 they go totally blind with no treatment. According to the release, by identifying the canines carrying this disease before they lose vision, this can be then used as a tool to guide breeding decisions to prevent the passing of the disease onto puppies.1 Historically, owners did not realize their dog had PRA until they were middle-aged, which means it could have been passed on to puppies if they had bred, making this a hard disease to control. “Once the dog’s eyesight starts to fail there’s no treatment ...
Post a Comment
Read more